Perspectives from the REPRISE III randomised trial

This video is offered by Boston Scientific


Lars Sondergaard, Denmark talks about the REPRISE III trial, presented at EuroPCR 2017. A prospective, randomised investigation of a novel transcathether aortic valve implantation system, the trial compares the Lotus valve and the CoreValve, with findings that show the far better performance of the Lotus valve in minimising paravalvular leak (PVL).
As the only mechanical expandable valve with an adaptive sealing, the Lotus valve allows for result assessment before the valve is deployed, letting the physician reposition it as needed, which makes it unique on the market.